Oxford Immunotec Global (NASDAQ:OXFD) Cut to “Strong Sell” at BidaskClub

BidaskClub downgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday, June 26th, BidAskClub reports.

OXFD has been the subject of a number of other reports. Zacks Investment Research downgraded shares of HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, April 1st. TheStreet downgraded shares of Viavi Solutions from a b- rating to a c+ rating in a research report on Monday, June 3rd. Finally, Piper Jaffray Companies set a $4.00 price objective on shares of Insys Therapeutics and gave the company a sell rating in a research note on Friday, March 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $18.00.

OXFD stock traded up $0.19 during trading hours on Wednesday, reaching $13.10. 202,061 shares of the stock were exchanged, compared to its average volume of 173,810. Oxford Immunotec Global has a 12 month low of $11.66 and a 12 month high of $19.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. The company has a market cap of $350.63 million, a P/E ratio of 25.57 and a beta of 0.35. The firm’s 50-day simple moving average is $14.07.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. The business had revenue of $14.79 million during the quarter, compared to analysts’ expectations of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. Oxford Immunotec Global’s quarterly revenue was up 26.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) earnings per share. Equities analysts expect that Oxford Immunotec Global will post -0.24 earnings per share for the current year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at $48,150. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.21% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA grew its stake in shares of Oxford Immunotec Global by 59,988.9% during the first quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after buying an additional 5,399 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Oxford Immunotec Global by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after buying an additional 5,120 shares during the last quarter. Campbell & CO Investment Adviser LLC grew its stake in shares of Oxford Immunotec Global by 15.0% during the second quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after buying an additional 3,255 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Oxford Immunotec Global by 50.7% in the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock worth $419,000 after purchasing an additional 11,022 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Oxford Immunotec Global by 972.3% in the first quarter. Acadian Asset Management LLC now owns 33,969 shares of the company’s stock worth $586,000 after purchasing an additional 30,801 shares during the last quarter. 91.18% of the stock is currently owned by hedge funds and other institutional investors.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Story: What is the price-to-earnings growth (PEG) ratio?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.